Results of a study comparing the stability, efficacy, and adverse effect profile of innovator formulation, latanoprost (Xalatan) ophthalmic solution 0.005%, with that of a new formulation of a latanoprost ophthalmic solution containing cyclodextrins.
Tressler
Charles S
CS
Bean
Gerald W
GW
D003505:Cyclodextrins / Q000737:chemistry*; D004340:Drug Contamination / Q000517:prevention & control; D004349:Drug Packaging; D004355:Drug Stability; D004356:Drug Storage; D005902:Glaucoma, Open-Angle / Q000188:drug therapy; D006801:Humans; D006940:Hyperemia / Q000139:chemically induced*; D000077338:Latanoprost; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000737:chemistry; D011310:Preservatives, Pharmaceutical / Q000737:chemistry; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects* / Q000737:chemistry; D013696:Temperature; D013997:Time Factors; D016896:Treatment Outcome
D003505:Cyclodextrins; D009883:Ophthalmic Solutions; D011310:Preservatives, Pharmaceutical; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost